Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
10.73
-0.37 (-3.33%)
At close: Jul 24, 2026, 4:00 PM EDT
11.02
+0.29 (2.70%)
Pre-market: Jul 27, 2026, 5:30 AM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Intellia Therapeutics stock has a consensus rating of "Buy" and an average price target of $26.17. The average 1-year stock price forecast is 143.90% higher than the current stock price, while the lowest is $8.00 (-25.44%) and the highest is $95 (+785.37%).
Price Target: $26.17 (+143.90%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 13 | 13 | 11 | 10 | 9 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 11 | 9 | 9 | 9 | 8 | 7 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 2 |
| Total | 25 | 25 | 25 | 23 | 22 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Sell Downgrades $9 | Sell | Downgrades | $9 | -16.12% | Jul 15, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Hold Maintains $12 → $17 | Hold | Maintains | $12 → $17 | +58.43% | Jul 10, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $49 | Buy | Maintains | $49 | +356.66% | Jun 16, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Maintains $19 | Hold | Maintains | $19 | +77.07% | Jun 16, 2026 |
| Goldman Sachs | Goldman Sachs | Sell Maintains $9 | Sell | Maintains | $9 | -16.12% | Jun 15, 2026 |
Financial Forecast
Revenue This Year
59.25M
from 67.67M
Decreased by -12.45%
Revenue Next Year
268.42M
from 59.25M
Increased by 353.05%
EPS This Year
-3.14
from -3.81
EPS Next Year
-1.76
from -3.14
EPS and Forward PE are based on non-GAAP adjusted numbers.